Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine in Asthma: Current Approach and Future Perspectives
share announcement

Personalized Medicine in Asthma: Current Approach and Future Perspectives

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (5 January 2024) | Viewed by 6839

Special Issue Editors

Dr. Raffaele Campisi

E-Mail Website1 Website2 Website3
Guest Editor
1. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
2. Respiratory Medicine Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy
Interests: severe asthma; airways diseases; bronchiectasis; airways immunology; respiratory failure; respiratory supports
Dr. Santi Nolasco

E-Mail Website1 Website2 Website3
Guest Editor
Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
Interests: airways diseases; airways immunology; severe asthma; bronchiectasis; respiratory failures; respiratory supports

Special Issue Information

Dear Colleagues,

Asthma is a heterogeneous chronic respiratory disorder that affects more than 300 million people worldwide, characterized by airway inflammation, hyperresponsiveness of bronchi, and often reversible bronchial obstruction.

During the last decade, clinical and translational findings have led to the dichotomization of asthma according to type 2 inflammation biomarkers, namely, blood and sputum eosinophils, FeNO and serum IgE count, into “type 2-high” and “type 2-low” subtypes.

The introduction of biologic therapies as add-on treatment in severe asthma has further increased the need of asthma clustering, making the determination of asthma endotypes, phenotypes and comorbidities a key point for a tailored approach.

We are pleased to invite you to contribute to this Special Issue about personalized medicine in asthma. The aim of this Special Issue is to gather evidence for the current approaches for asthma, and to provide future perspectives by finding new roles for the well-known biomarkers and inflammatory cytokines, proposing new approaches in asthma management and its related comorbidities.

We look forward to receiving your contributions.

Dr. Raffaele Campisi
Dr. Santi Nolasco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • severe asthma
  • bronchiectasis
  • airways remodeling
  • airways inflammation
  • biologic therapy
  • biomarkers
  • blood eosinophils
  • inflammatory cytokines
  • sputum eosinophils
  • type 2 inflammation
  • mucus plugs
  • small airways diseases
  • asthma remission
  • personalized medicine
  • asthma endotypes
  • asthma phenotypes

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

4 pages, 564 KiB  
Editorial
Personalized Medicine in Asthma: Current Approach and Future Perspectives
by Santi Nolasco, Claudia Crimi and Raffaele Campisi
J. Pers. Med. 2023, 13(10), 1459; https://doi.org/10.3390/jpm13101459 - 30 Sep 2023
Cited by 1 | Viewed by 1256
Abstract
Asthma is one of the most common chronic respiratory diseases, affecting over 300 million people worldwide [...] Full article
(This article belongs to the Special Issue Personalized Medicine in Asthma: Current Approach and Future Perspectives)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial

22 pages, 1827 KiB  
Review
Combination of Biological Therapy in Severe Asthma: Where We Are?
by Lorenzo Carriera, Marta Fantò, Alessia Martini, Alice D’Abramo, Genesio Puzio, Marco Umberto Scaramozzino and Angelo Coppola
J. Pers. Med. 2023, 13(11), 1594; https://doi.org/10.3390/jpm13111594 - 10 Nov 2023
Cited by 3 | Viewed by 1669
Abstract
Biological drugs have revolutionized the management of severe asthma. However, a variable number of patients remain uncontrolled or only partially controlled even after the appropriate administration of a biologic agent. The combination of two biologics may target different inflammatory pathways, and it has [...] Read more.
Biological drugs have revolutionized the management of severe asthma. However, a variable number of patients remain uncontrolled or only partially controlled even after the appropriate administration of a biologic agent. The combination of two biologics may target different inflammatory pathways, and it has been used in patients suffering from uncontrolled severe asthma with evidence of both allergic and eosinophilic phenotypes or severe asthma and type2 comorbidities. Combination therapy has also been used to handle anti-IL4/13R induced hypereosinophilia. There is insufficient data on combining biologics for the treatment of severe uncontrolled asthma and type 2 comorbidities, also because of the high cost, and currently no guideline recommends dual biologic therapy. A systematic search was performed using the Medline and Scopus databases. Published data on concurrent administration of two biological drugs in severe, uncontrolled asthma patients has been reported in 28 real-world studies and 1 clinical trial. Data extraction was followed by a descriptive and narrative synthesis of the findings. Future studies should be conducted to further assess the safety, efficacy, and cost-effectiveness of this therapeutic strategy. Full article
(This article belongs to the Special Issue Personalized Medicine in Asthma: Current Approach and Future Perspectives)
►▼ Show Figures

Figure 1

15 pages, 649 KiB  
Review
Asthma-COPD Overlap in Clinical Practice (ACO_CP 2023): Toward Precision Medicine
by Ahmad R. Alsayed, Mahmoud S. Abu-Samak and Mohammad Alkhatib
J. Pers. Med. 2023, 13(4), 677; https://doi.org/10.3390/jpm13040677 - 18 Apr 2023
Cited by 6 | Viewed by 3274
Abstract
Asthma and COPD have characteristic symptoms, yet patients with both are prevalent. Despite this, there is currently no globally accepted definition for the overlap between asthma and COPD, commonly referred to as asthma–COPD overlap (ACO). Generally, ACO is not considered a distinct disease [...] Read more.
Asthma and COPD have characteristic symptoms, yet patients with both are prevalent. Despite this, there is currently no globally accepted definition for the overlap between asthma and COPD, commonly referred to as asthma–COPD overlap (ACO). Generally, ACO is not considered a distinct disease or symptom from either clinical or mechanistic perspectives. However, identifying patients who present with both conditions is crucial for guiding clinical therapy. Similar to asthma and COPD, ACO patients are heterogeneous and presumably have multiple underlying disease processes. The variability of ACO patients led to the establishment of multiple definitions describing the condition’s essential clinical, physiological, and molecular characteristics. ACO comprises numerous phenotypes, which affects the optimal medication choice and can serve as a predictor of disease prognosis. Various phenotypes of ACO have been suggested based on host factors including but not limited to demographics, symptoms, spirometric findings, smoking history, and underlying airway inflammation. This review provides a comprehensive clinical guide for ACO patients to be used in clinical practice based on the available limited data. Future longitudinal studies must evaluate the stability of ACO phenotypes over time and explore their predictive powers to facilitate a more precise and effective management approach. Full article
(This article belongs to the Special Issue Personalized Medicine in Asthma: Current Approach and Future Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop